The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema

被引：0

作者：

Maria Vittoria Cicinelli

Amir Rosenblatt

Domenico Grosso

Piero Zollet

Luigi Capone

Alessandro Rabiolo

Rosangela Lattanzio

Anat Loewenstein

Francesco Bandello

机构：

[1] Vita-Salute San Raffaele University,School of Medicine

[2] IRCCS San Raffaele Scientific Institute,Department of Ophthalmology

[3] Tel-Aviv Sourasky Medical Center,Division of Ophthalmology

[4] Tel-Aviv University,Sackler Faculty of Medicine

[5] Gloucestershire Hospitals NHS Foundation Trust,Department of Ophthalmology

[6] Ophthalmological Unit,Department of Clinical Sciences and Community Health

[7] Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico,Department of Medical Retina

[8] University of Milan,Department of Medical Retina

[9] Singapore National Eye Centre,Smt. Kanuri Santhamma Retina Vitreous Centre LV

[10] Singapore Eye Research Institute,Department of Ophthalmology

[11] Duke-NUS Medical School,Service d’ophtalmologie

[12] Aneurin Bevan University Health Board,Kaplan Medical Centre, department of ophthalmology

[13] Prasad Eye Institute,Department of Ophthalmology

[14] University of British Columbia,Department of Retina and Vitreous

[15] hôpital Avicenne DHU Sight Restore,Department of ophthalmology

[16] Affiliated to Hadassah School of medicine,Charité – Universitätsmedizin Berlin

[17] Cantonal Hospital Lucerne,Centre for Vision Research

[18] Moorfields Eye Hospital NHS Foundation Trust,Department of Ophthalmology

[19] UCL Institute of Health Informatics,Department of Ophthalmology

[20] NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology,2nd Department of Ophthalmology

[21] Clínica de Oftalmología de Cali,Department of Ophthalmology

[22] Ophthalmic department Fondazione Policlinico Universitario Agostino Gemelli IRCCS,State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center

[23] Università Cattolica del Sacro Cuore,Department of Ophthalmology

[24] Pitié Salpêtrière University Hospital Sorbonne Université,Department of Ophthalmology

[25] Clínica oftalmológica Santa Lucía,Department of Ophthalmology

[26] corporate member of Freie Universität Berlin Humboldt Universität zu Berlin,undefined

[27] and Berlin Institute of Health,undefined

[28] The Westmead Institute for Medical Research University of Sydney,undefined

[29] Altino Ventura Foundation,undefined

[30] HOPE Eye Hospital,undefined

[31] Attikon Hospital National and Kapodistrian University of Athens,undefined

[32] Faculty of Medicine Siriraj Hospital Mahidol University,undefined

[33] Department of Ophthalmology Puerta de Hierro-Majadahonda University Hospital,undefined

[34] Ocular Microsurgery Institute (IMO),undefined

[35] Sun Yat-sen University,undefined

[36] Yeni Yuzyil University,undefined

[37] Department of Ophthalmology,undefined

[38] Ludwig-Maximilians-University,undefined

[39] National University of Malaysia,undefined

[40] University of Buenos Aires,undefined

来源：

Eye | 2021年 / 35卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：3232 / 3242

页数：10

共 50 条

[21] Fluocinolone acetonide intravitreal implant in patients with diabetic macular edema: 12 month results
Pearson, P
Baker, CW
Eliott, D
Ip, MS
Morse, LS
Callanan, D
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 : U489 - U489
[22] Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN®): A Review in Diabetic Macular Edema
Syed, Yahiya Y.
DRUGS, 2017, 77 (05) : 575 - 583
[23] Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment
Rehak, Matus
Busch, Catharina
Unterlauft, Jan-Darius
Jochmann, Claudia
Wiedemann, Peter
ACTA DIABETOLOGICA, 2020, 57 (04) : 469 - 478
[24] Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment
Matus Rehak
Catharina Busch
Jan-Darius Unterlauft
Claudia Jochmann
Peter Wiedemann
Acta Diabetologica, 2020, 57 : 469 - 478
[25] Early experience and outcome of Fluocinalone acetonide intravitreal implant (Iluvien) in the treatment of chronic diabetic macular oedema
Vaideanu-Collins, Daniela
Vig, Julia
Manvikar, Sree
El-Ghrably, Ibraheem
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
[26] Three-year outcome of fluocinolone acetonide intravitreal implant (ILUVIEN) in the treatment of chronic diabetic macular oedema: real-world results in the UK
Alfaqawi, Fadi
Sarmad, Ambreen
Lip, Peck-Lin
Elsherbiny, Samer
Chavan, Randhir
Mitra, Arijit
Mushtaq, Bushra
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
[27] Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema
Mehta, Hemal
Gillies, Mark
Fraser-Bell, Samantha
THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2015, 6 (05) : 234 - 245
[28] Budget impact analysis of dexamethasone intravitreal implant for the treatment of diabetic macular oedema
Cervera, Enrique
de Andres-Nogales, Fernando
Armada, Felix
Arias, Luis
Oyaguez, Itziar
Martinez, Concha
FARMACIA HOSPITALARIA, 2018, 42 (06) : 244 - 250
[29] EFFECT OF DEXAMETHASONE INTRAVITREAL IMPLANT, OZURDEX®, ON DIABETIC MACULAR OEDEMA DURING PREGNANCY
Ba-Ali, S.
Valerius, M.
Hodzic-Hadzibegovic, D.
Tornes, M. H.
Lund-Andersen, H.
EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2016, 26 (04) : E110 - E110
[30] Fluocinolone acetonide ( FAc) 0.2 mg intravitreal implant in the treatment of diabetic macular edema (DME)
Liu, John
Coney, Joseph
Schartman, Jerome
Miller, David G.
Zegarra, Hernando
Rao, Llewelyn
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)

← 1 2 3 4 5 →